miR-145靶向调控DAB2对前列腺癌PC3细胞迁移和侵袭能力的影响
收稿日期: 2013-08-29
修回日期: 2013-09-29
网络出版日期: 2013-12-20
基金资助
教育部“新世纪优秀人才支持计划”(编号：NCET-09-0541)资助
Effects of miR-145 on the migration and invasion of prostate cancer PC3 cells by targeting DAB2
Received date: 2013-08-29
Revised date: 2013-09-29
Online published: 2013-12-20
已有研究表明, miR-145在多种肿瘤中低表达, 并与细胞增殖和转移相关。文章通过生物信息学分析并结合体外实验鉴定, 发现DAB2(Disabled homolog 2)为miR-145在肿瘤转移过程中累及的新靶点。DAB2一直被认为是一个重要的抑癌基因, 在多种肿瘤标本中表达低下。然而, 研究发现, 在具高侵袭能力的前列腺癌细胞株PC3中DAB2基因却呈较高水平表达。另外, 外源表达miR-145能显著下调 DAB2表达水平, 并抑制PC3细胞的迁移和侵袭能力, 且这种miR-145诱导的PC3细胞功能缺陷能被DAB2过表达修复。上述结果表明, miR-145能通过靶向调控DAB2而影响高侵袭前列腺癌细胞的迁移和侵袭能力。
谢树高, 谢银银, 张元亮,黄秋花 . miR-145靶向调控DAB2对前列腺癌PC3细胞迁移和侵袭能力的影响[J]. 遗传, 2014 , 36(1) : 50 -57 . DOI: 10.3724/SP.J.1005.2014.00050
It was reported that miR-145, which is significantly decreased in a variety of tumor cells, is associated with cell proliferation and metastasis. In this study, using bioinformatics analysis and in vitro assays, we identified DAB2 (Disabled homolog 2) as a downstream target gene of miR-145 during tumor metastasis process. DAB2 has been characterized as an important tumor suppressor, and is usually expressed at low levels in tumor cells. However, in this study, the relative high-level expression of DAB2 gene was observed in the highly invasive prostate cancer PC3 cells. Moreover, enforced expression of miR-145 could significantly down-regulate the expression level of DAB2 in PC3 cells, and inhibit the migration and invasion of PC3 cells. Notably, dysfunction of PC3 cells induced by miR-145 overexpression can be rescued by co-overexpression of DAB2. These results demonstrate that miR-145 regulates the migration and invasion of highly invasive prostate cancer cells through targeting DAB2 gene.
Key words： miR-145; DAB2; prostate cancer cell PC3; cell migration and invasion
[1] Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res, 2007, 67(13): 6130–6135. <\p>
[2] Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene, 2008, 27(12): 1788–1793. <\p>
[3] Michael MZ, SM OC, Van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003, 1(12): 882–891. <\p>
[4] Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology, 2009, 77(1): 12–21. <\p>
[5] Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 2006, 16(4): 845–850. <\p>
[6] Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Mat-subara H. miR-145, miR-133a and miR-133b: Tu-mor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer, 2010, 127(12): 2804–2814. <\p>
[7] Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Morenó I, Monzo M, García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer, 2006, 5: 29. <\p>
[8] Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yo-shino H, Nohata N, Fuse M, Seki N, Nakagawa M. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate, 2011, 71(14), doi: 10.1002/pros.21372. <\p>
[9] Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic reg-ulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem, 2003, 278(5): 3121–3130. <\p>
[10] Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shi-mizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res, 2004, 10(6): 2082–2089. <\p>
[11] Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer, 2005, 92(6): 1117–1125. <\p>
[12] Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Ha-nabata T, Aoe M, Date H, Gazdar AF, Shimizu N. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer, 2005, 113(1): 59–66. <\p>
[13] Prunier C, Howe PH. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to me-senchymal transition (EMT). J Biol Chem, 2005, 280(17): 17540–17548. <\p>
[14] Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene, 2003, 22(46): 7155–7169. <\p>
[15] Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun YP, Sanicola M, Salomon DS. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol, 2004, 201(2): 266–276. <\p>
[16] Yang JL, Du XL. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surg Oncol, 2013, 22(3): e53–e57. <\p>
[17] Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA- 187 through ta
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
